S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years

At a recent analyst meeting, senior executives from US drug major Schering-Plough explained that, with several potential blockbusters under review and in late-stage testing, S-P has one of the best pipelines in the industry.

Company chief executive Fred Hassan highlighted seven drugs that S-P hopes to launch over the next four years that could each generate over $1.0 billion in annual revenues.

"Our scientists have built a pipeline that we believe is the best in our history and one of the best in the industry, with nine New Molecular Entities in Phase III, plus three in pre-registration," he said.